STAAR Surgical Shares Outstanding 2012-2026 | STAA
STAAR Surgical shares outstanding from 2012 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
STAAR Surgical Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025 | 50 |
| 2024 | 49 |
| 2023 | 49 |
| 2022 | 49 |
| 2021 | 49 |
| 2020 | 48 |
| 2019 | 47 |
| 2018 | 45 |
| 2017 | 41 |
| 2016 | 40 |
| 2015 | 39 |
| 2014 | 38 |
| 2013 | 39 |
| 2012 | 36 |
| 2011 | 37 |
|
STAAR Surgical Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2026-03-31 | 51 |
| 2025-12-31 | 50 |
| 2025-09-30 | 51 |
| 2025-06-30 | 50 |
| 2025-03-31 | 49 |
| 2024-12-31 | 49 |
| 2024-09-30 | 50 |
| 2024-06-30 | 50 |
| 2024-03-31 | 49 |
| 2023-12-31 | 49 |
| 2023-09-30 | 49 |
| 2023-06-30 | 50 |
| 2023-03-31 | 50 |
| 2022-12-31 | 49 |
| 2022-09-30 | 50 |
| 2022-06-30 | 49 |
| 2022-03-31 | 49 |
| 2021-12-31 | 49 |
| 2021-09-30 | 50 |
| 2021-06-30 | 49 |
| 2021-03-31 | 49 |
| 2020-12-31 | 48 |
| 2020-09-30 | 48 |
| 2020-06-30 | 45 |
| 2020-03-31 | 45 |
| 2019-12-31 | 47 |
| 2019-09-30 | 47 |
| 2019-06-30 | 47 |
| 2019-03-31 | 47 |
| 2018-12-31 | 45 |
| 2018-09-30 | 46 |
| 2018-06-30 | 44 |
| 2018-03-31 | 43 |
| 2017-12-31 | 41 |
| 2017-09-30 | 42 |
| 2017-06-30 | 41 |
| 2017-03-31 | 41 |
| 2016-12-31 | 40 |
| 2016-09-30 | 40 |
| 2016-06-30 | 40 |
| 2016-03-31 | 40 |
| 2015-12-31 | 39 |
| 2015-09-30 | 40 |
| 2015-06-30 | 39 |
| 2015-03-31 | 38 |
| 2014-12-31 | 38 |
| 2014-09-30 | 38 |
| 2014-06-30 | 38 |
| 2014-03-31 | 38 |
| 2013-12-31 | 39 |
| 2013-09-30 | 39 |
| 2013-06-30 | 38 |
| 2013-03-31 | 37 |
| 2012-12-31 | 36 |
| 2012-09-30 | 36 |
| 2012-06-30 | 36 |
| 2012-03-31 | 38 |
| 2011-12-31 | 37 |
| 2011-09-30 | 37 |
| 2011-06-30 | 36 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical & Dental Supplies | $1.309B | $0.239B |
| Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| McKesson (MCK) | United States | $106.025B | 23.03 |
| Cardinal Health (CAH) | United States | $50.715B | 22.43 |
| Becton Dickinson (BDX) | United States | $43.913B | 11.10 |
| West Pharmaceutical Services (WST) | United States | $18.493B | 35.19 |
| Straumann Holding AG (SAUHY) | Switzerland | $16.902B | 0.00 |
| Cooper (COO) | United States | $13.894B | 16.52 |
| Align Technology (ALGN) | United States | $12.400B | 21.09 |
| Henry Schein (HSIC) | United States | $8.645B | 15.16 |
| Merit Medical Systems (MMSI) | United States | $4.072B | 19.84 |
| DENTSPLY SIRONA (XRAY) | United States | $2.339B | 7.36 |
| CONMED (CNMD) | United States | $1.107B | 7.97 |
| Pro-Dex (PDEX) | United States | $0.165B | 19.65 |
| Lifevantage (LFVN) | United States | $0.053B | 5.46 |
| Axe Compute (AGPU) | United States | $0.022B | 0.00 |